Module 1: HER2-Positive Breast Cancer (BC)

DISCUSSION TOPICS

• Indications for neoadjuvant systemic therapy and selection of optimal approach
• Importance of age, nodal status and planned surgical approach in the use of neoadjuvant systemic therapy for patients with HER2-positive BC
• Results from the Phase III APHINITY trial evaluating the addition of pertuzumab to chemotherapy and trastuzumab as adjuvant therapy for HER2-positive primary BC
• Monitoring patients for cardiac side effects during adjuvant anti-HER2 therapy; care considerations for patients receiving anthracycline versus nonanthracycline regimens
• FDA approval of neratinib as extended adjuvant therapy; patient selection and clinical factors guiding its use in clinical practice
• Common side effects observed with neratinib; potential strategies to mitigate associated gastrointestinal toxicity
• Clinical factors influencing the sequencing of anti-HER2 agents in the metastatic setting; integration of T-DM1 into the treatment algorithm
• Efficacy and safety of neratinib/capecitabine for patients with HER2-positive BC and brain metastases; other available agents and strategies with CNS activity
• Ongoing trials evaluating novel agents and strategies for patients with HER2-positive BC

Module 2: ER-Positive, HER2-Negative BC

DISCUSSION TOPICS

• Optimizing first-line systemic therapy for patients with metastatic ER-positive BC; impact of prior hormonal therapy, symptomatology, performance status and disease-free interval
• Comparative activity, side effects and CNS penetration of available CDK4/6 inhibitors
• Recent FDA approvals of ribociclib and abemaciclib and integration into clinical algorithms for ER-positive metastatic BC
• Available data with and current clinical role of CDK4/6 inhibitors for premenopausal patients
• Incidence, monitoring and treatment of commonly occurring toxicities in patients receiving CDK4/6 inhibitors
• Incorporating everolimus into the treatment algorithm for patients with ER-positive metastatic BC
• Prevention and management of everolimus-associated mucositis/stomatitis

Module 3: Triple-Negative BC

DISCUSSION TOPICS

• Indications for BRCA mutation testing in patients with BC; implications of a BRCA1/2 germline mutation for prognosis and current therapeutic selection
• Biologic rationale for the evaluation of PARP inhibitors in patients with BRCA1/2 germline mutations
• Recent FDA approval of olaparib and Phase III results from the OlympiAD trial documenting a progression-free survival advantage with olaparib versus chemotherapy for germline BRCA mutation-positive, HER2-negative metastatic BC
• Ongoing clinical trials of PARP inhibitors (niraparib, veliparib, et cetera) in patients with early and advanced BC
• Available data with and ongoing evaluation of anti-PD-1/PD-L1 antibodies as monotherapy or in combination with other systemic agents